Pharmaceutical company Moderna Inc (NASDAQ: MRNA) announced on Tuesday that it has achieved successful Phase 3 trial results for mRNA-1283, its next-generation COVID-19 vaccine. Compared to its licensed vaccine mRNA-1273.222, mRNA-1283 induces a stronger immune response against SARS-CoV-2, particularly in individuals over 65.
The NextCOVE trial involved over 11,400 participants aged 12 and above across the US, UK and Canada. mRNA-1283 demonstrates a similar safety profile to Moderna's approved COVID-19 vaccines.
mRNA-1283's storage, shelf life, and pre-filled syringe presentation could ease healthcare provider burden and enhance accessibility in various settings. Detailed trial data will be presented at Moderna's Vaccines Day event on 27 March 2024.
Moderna's mRNA platform has revolutionised medicine development, delivering rapid and efficient solutions for infectious diseases, immuno-oncology, rare diseases and autoimmune conditions. The company's mission is to create a healthier future through innovative mRNA medicines.
Renew Biotechnologies names new chief operating officer
Teva, Sanofi accelerate inflammatory bowel disease drug trial
Ro adds David B Allison to Advisory Board
Charles River Laboratories and Autobahn Labs forge alliance to boost academic drug discovery
Nkarta partnering with Columbia on investigator-led lupus trial for NKX019
Gilead's lenacapavir demonstrates 100% efficacy in HIV prevention trial
Anixa Biosciences' ovarian cancer CAR-T therapy individual patient IND receives FDA approval
Evergreen Nephrology names new director
Emmaus Life Sciences names new chief executive officer
FDA feedback boosts Diamyd Medical's pathway to accelerated approval for Type 1 Diabetes Therapy
TC BioPharm (Holdings) doses sixth patient in TCB-008 clinical trial
Caidya names new chief executive officer
Ionis Pharmaceuticals reports positive results for ION582 in Angelman syndrome study
Nuvalent launches HEROEX-1 trial for HER2-selective inhibitor NVL-330
Astellas and Osaka University collaborate on stem cell therapy for disc degeneration